LT2002123A - Novel interferon for the treatment of multiple sclerosis - Google Patents
Novel interferon for the treatment of multiple sclerosisInfo
- Publication number
- LT2002123A LT2002123A LT2002123A LT2002123A LT2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A
- Authority
- LT
- Lithuania
- Prior art keywords
- multiple sclerosis
- treatment
- ifn
- biologically
- novel interferon
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 229920001184 polypeptide Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Chemical group 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21204600P | 2000-06-16 | 2000-06-16 | |
| US09/881,050 US20020025304A1 (en) | 2000-06-16 | 2001-06-15 | Novel interferon for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2002123A true LT2002123A (en) | 2003-06-25 |
Family
ID=26906704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2002123A LT2002123A (en) | 2000-06-16 | 2002-12-02 | Novel interferon for the treatment of multiple sclerosis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020025304A1 (pl) |
| EP (1) | EP1289541A2 (pl) |
| JP (1) | JP2004505021A (pl) |
| KR (1) | KR20030009529A (pl) |
| CN (1) | CN1436086A (pl) |
| AU (1) | AU2001267099A1 (pl) |
| BG (1) | BG107370A (pl) |
| BR (1) | BR0111852A (pl) |
| CA (1) | CA2413077A1 (pl) |
| CZ (1) | CZ20024094A3 (pl) |
| EE (1) | EE200200693A (pl) |
| HU (1) | HUP0300787A2 (pl) |
| IL (1) | IL152996A0 (pl) |
| LT (1) | LT2002123A (pl) |
| MX (1) | MXPA02012308A (pl) |
| NO (1) | NO20025964L (pl) |
| NZ (1) | NZ522849A (pl) |
| PL (1) | PL359562A1 (pl) |
| RU (1) | RU2003100517A (pl) |
| SI (1) | SI21080A (pl) |
| SK (1) | SK17612002A3 (pl) |
| WO (1) | WO2001095929A2 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| EP1565205A4 (en) * | 2002-11-18 | 2006-07-05 | Maxygen Inc | Interferon-alpha polypeptides and conjugates |
| EP1712992A1 (en) * | 2005-04-11 | 2006-10-18 | Sony Ericsson Mobile Communications AB | Updating of data instructions |
| EP2536435B1 (en) | 2010-02-18 | 2017-11-15 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP3743448A4 (en) | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| WO2024192373A1 (en) * | 2023-03-16 | 2024-09-19 | A-Alpha Bio | Interferon alpha-2 variants |
| US12281147B2 (en) | 2023-08-14 | 2025-04-22 | A-Alpha Bio, Inc. | Interleukin 21 variants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| HUT76099A (en) * | 1994-05-10 | 1997-06-30 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis |
| EP1037995A1 (en) * | 1997-12-08 | 2000-09-27 | Genentech, Inc. | Human interferon-epsilon: a type 1 interferon |
| SK17762000A3 (sk) * | 1998-05-29 | 2001-07-10 | Biogen, Inc. | Farmaceutický prípravok obsahujúci rekombinantný ľudský interferón beta-1a |
| JP2002526078A (ja) * | 1998-09-18 | 2002-08-20 | ザイモジェネティクス，インコーポレイティド | インターフェロン−イプシロン |
| AU2001255380A1 (en) * | 2000-04-14 | 2001-10-30 | Zymogenetics Inc. | Human interferon, zinf2 |
-
2001
- 2001-06-15 US US09/881,050 patent/US20020025304A1/en not_active Abandoned
- 2001-06-18 CA CA002413077A patent/CA2413077A1/en not_active Abandoned
- 2001-06-18 BR BR0111852-8A patent/BR0111852A/pt not_active Application Discontinuation
- 2001-06-18 RU RU2003100517/15A patent/RU2003100517A/ru not_active Application Discontinuation
- 2001-06-18 MX MXPA02012308A patent/MXPA02012308A/es unknown
- 2001-06-18 SK SK1761-2002A patent/SK17612002A3/sk unknown
- 2001-06-18 EE EEP200200693A patent/EE200200693A/xx unknown
- 2001-06-18 PL PL01359562A patent/PL359562A1/pl not_active Application Discontinuation
- 2001-06-18 SI SI200120032A patent/SI21080A/sl not_active IP Right Cessation
- 2001-06-18 IL IL15299601A patent/IL152996A0/xx unknown
- 2001-06-18 HU HU0300787A patent/HUP0300787A2/hu unknown
- 2001-06-18 WO PCT/US2001/041022 patent/WO2001095929A2/en not_active Ceased
- 2001-06-18 EP EP01944716A patent/EP1289541A2/en not_active Withdrawn
- 2001-06-18 AU AU2001267099A patent/AU2001267099A1/en not_active Abandoned
- 2001-06-18 JP JP2002510107A patent/JP2004505021A/ja active Pending
- 2001-06-18 KR KR1020027017090A patent/KR20030009529A/ko not_active Withdrawn
- 2001-06-18 CZ CZ20024094A patent/CZ20024094A3/cs unknown
- 2001-06-18 CN CN01811184A patent/CN1436086A/zh active Pending
- 2001-06-18 NZ NZ522849A patent/NZ522849A/en unknown
-
2002
- 2002-12-02 LT LT2002123A patent/LT2002123A/xx unknown
- 2002-12-11 BG BG107370A patent/BG107370A/xx unknown
- 2002-12-12 NO NO20025964A patent/NO20025964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20024094A3 (cs) | 2003-05-14 |
| AU2001267099A1 (en) | 2001-12-24 |
| PL359562A1 (pl) | 2004-08-23 |
| JP2004505021A (ja) | 2004-02-19 |
| HUP0300787A2 (hu) | 2003-07-28 |
| NO20025964D0 (no) | 2002-12-12 |
| WO2001095929A3 (en) | 2002-10-10 |
| CA2413077A1 (en) | 2001-12-20 |
| CN1436086A (zh) | 2003-08-13 |
| SK17612002A3 (sk) | 2003-08-05 |
| KR20030009529A (ko) | 2003-01-29 |
| WO2001095929A2 (en) | 2001-12-20 |
| BG107370A (en) | 2003-11-28 |
| EE200200693A (et) | 2004-06-15 |
| RU2003100517A (ru) | 2004-06-27 |
| BR0111852A (pt) | 2003-05-20 |
| EP1289541A2 (en) | 2003-03-12 |
| NO20025964L (no) | 2003-02-14 |
| SI21080A (sl) | 2003-06-30 |
| IL152996A0 (en) | 2003-06-24 |
| US20020025304A1 (en) | 2002-02-28 |
| MXPA02012308A (es) | 2003-04-25 |
| NZ522849A (en) | 2004-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
| PT735818E (pt) | Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y | |
| MX9703643A (es) | Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana. | |
| EP0662827A4 (en) | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS. | |
| PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
| HUP0004853A3 (en) | Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| EP1033998A4 (en) | METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER | |
| BRPI9710372B8 (pt) | composto, e, composição farmacêutica. | |
| IL138665A0 (en) | Peptide factor | |
| WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
| IL136737A0 (en) | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | |
| LT2002123A (en) | Novel interferon for the treatment of multiple sclerosis | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| SI1082131T1 (en) | Immunoregulator | |
| EP1501936A4 (en) | PROTEIN FAMILY OF CYTOKINE | |
| DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
| IL134263A0 (en) | Use of phanquinone for the treatment of alzheimer's disease | |
| CA2433785A1 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
| UA83989C2 (ru) | Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение | |
| YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
| IL145722A0 (en) | Pharmaceutical composition comprising growth hormone and interferon | |
| ATE371737T1 (de) | Proteaseresistente flint-analoge | |
| DK0938329T3 (da) | Immunogen TLP sammensætning | |
| HUT77422A (hu) | Humán dezoxiribonukleáz I variánsok |